All cancer types
Results
Phase 1
This trial looked at a drug called Phortress for advanced cancer. The trial was supported by Cancer Research UK.
Phortress is called a ‘pro drug’. This means it is not an active drug when you have it, but changes into the active form in your body. The active form of Phortress is called 5F 203.
The theory is that 5F 203 then binds to genetic material (DNA) inside cancer cells. This means that the cell cannot function or reproduce properly and it dies.
Phortress had only been tested in the laboratory before. This trial was the first time it had been tested in people.
The aims of the trial were to find out
The best dose of Phortress to give
What happens to Phortress in the body
How well it works as an treatment for cancer
What the side effects are
Recruitment start: 28 April 2004
Recruitment end: 21 February 2012
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Ruth Plummer
Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)
Pharminox
This is Cancer Research UK trial number CRUKD/04/036.
Last reviewed: 09 Apr 2013
CRUK internal database number: 286
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
